九洲药业：目前业务发展趋势向好，订单量和项目数量日益丰富

Core Viewpoint - Jiuzhou Pharmaceutical (603456) has demonstrated a strong development trend in its peptide business, offering a one-stop service capability from custom peptide compounds to registration and commercial GMP production [1] Group 1: Business Development - The company has seen an increase in order volume and project numbers in its peptide business [1] - An additional annual production capacity of 800 kilograms for peptides is set to commence in 2025, with specific project orders already secured [1] - The overall capacity utilization rate for the company's peptide segment is expected to remain between 40% and 50% in 2026, aligning with current business plans and market demand [1]